

Funder	Project Title	Funding	Institution
Department of Defense - Autism Research Program	Metabolic signature of antipsychotics used in the treatment of autism	\$588,750	University of Cincinnati
Autism Speaks	Mirtazapine treatment of anxiety in children and adolescents with pervasive developmental disorders	\$99,993	Indiana University
National Institutes of Health	3/4-RUPP Autism Network: Guanfacine for the treatment of hyperactivity in PDD	\$393,205	University of California, Los Angeles
National Institutes of Health	4/4-RUPP Autism Network: Guanfacine for the treatment of hyperactivity in PDD	\$556,007	Yale University
National Institutes of Health	Targeted pharmacologic interventions for autism	\$363,488	Indiana University-Purdue University Indianapolis
National Institutes of Health	1/4-RUPP Autism Network: Guanfacine for the treatment of hyperactivity in PDD	\$337,175	Indiana University-Purdue University Indianapolis
National Institutes of Health	Pharmacotherapy of pervasive developmental disorders	\$184,540	Indiana University-Purdue University Indianapolis
National Institutes of Health	2/4-RUPP Autism Network: Guanfacine for the treatment of hyperactivity in PDD	\$311,729	Seattle Children's Hospital